Trypanosoma cruzi: In vitro and in vivo antiproliferative effects of Epigallocatechin gallate.

GUIDA, C.; ESTEVA, M.; CAMINO, A.; FLAWIÁ, M.M.; TORRES, H.N.; PAVETO, C.

EXPERIMENTAL PARASITOLOGY

Elsevier

Año: 2007 vol. 117 p. 188 - 194

0014-4894

The trypanocidal activity of catechins on Trypanosoma cruzi bloodstream trypomastigotes has been previously reported. Herein, we present the effect of epigallocatechin gallate (EGCg) on parasitemia and survival in a murine model of acute Chagas’ disease as well as on the epimastigote form of the parasite. Upon intraperitoneal administration of daily doses of 0.8 mg/kg/day of EGCg for 45 days, mice survival rates increased from 11% to 60%, while parasitemia diminished to 50%. No side effects were observed in EGCg-treated animals.Fifty percent inhibition of epimastigotes growth was achieved with 311 lM EGCg 120 h after drug addition. No lysis, total culture growth inhibition or morphological changes were observed upon addition of 1–3 mM EGCg at 24 h. This treatment also produced oligosomalfragmentation of epimastigotes DNA, suggesting a programmed cell death (PCD)-like process. All these findings point out EGCg as a potential new lead compound for chemotherapy of Chagas’ disease. 2007 Elsevier Inc. All rights reserved.